Star Guardian Sia Astelle Arrives in MapleStory M as the First, All-new Exclusive Character!
Last week, free-to-play mobile MMORPG MapleStory M from Nexon, brought the heavens down to Maple World with the release of its first original character, Sia Astelle. This brand-new Star Guardian (Magician class) has never been seen in other global versions of MapleStory, nor has the character been available in other versions of MapleStory M before!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005080/en/
Nexon America proudly introduces Sia Astelle, the first brand new, original character in MapleStory M. (Graphic: Business Wire)
Sia Astelle is the guardian of Oort, the home to the celestial order of stars. Her first duty is in service to the cosmos, guiding stars along their destined path. After a series of strange events occur, Sia arrives in Maple World when she is forced to leave her tranquil life on Oort behind.
In addition to the new Star Guardian character, MapleStory M’s latest update boasts a wide array of improvements and events to start the new year right, including max EXP stat increase from 250% to 300%, improvements to MapleStory M's end game gear Necro equipment, skill presets, and more.
Also, while playing as Sia Astelle, mobile Maplers can benefit from bonus rewards and events:
- Pre-creation reward (1/11 after maintenance until 1/25) A reward for players who participated in ‘Sia Astelle Pre-Creation event’.
- Growth mission event (1/11 after maintenance until 2/12) - Rewards available for Sia after reaching a certain level and completing certain missions.
- Mega Burning Plus event (1/11 after maintenance until 2/12) - Sia will earn an additional 2 levels every time the character levels up.
- Grow with Sia Astelle event (1/11 after maintenance until 2/12) - Rewards and EXP will be granted to another selected character player when Sia levels up.
Other celebratory events help ring in the new year in Maple World:
- New Year event: “I Just Wanted to Have a Fulfilling Year, but Being Hero Is Too Much!” (1/11 until 2/22) - A series of multiple mini-game events where players need to save the world by participating in various tasks such as delivering food, collecting coins while hunting, and climbing trees to avoid obstacles. Maplers can also take down Lord Pixrog in a boss battle and receive rewards based on the participation count.
- 2023 Happy New Year! event (1/18 until 2/1) - Players can open lucky red envelopes with 2023 Special Energy acquired through hunting.
- 2023 Lunar New Year 14-day Login event (1/18 until 2/8) - Players can log into MapleStory M for 14 consecutive days to earn rewards!
Visit the world of MapleStory M and experience the cosmic wonder of Sia Astelle! To learn more about MapleStory M, visit the App Store or Google Play Store page and follow @PlayMapleM on Twitter for the latest updates.
Assets: Image
Social Media: Facebook / Instagram / Twitter / Twitch / YouTube / Discord
About MapleStory M https://maplestorym.nexon.com/
MapleStory M, launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory to mobile, offering the same endless amount of customization, immersive storylines, and epic boss raids that fans have come to expect from the legendary franchise. MapleStory M quickly reached 10 million downloads within 100 days after global launch and celebrates its four-year anniversary in 2022 having 16 million total downloads globally.
About Nexon America Inc. https://www.nexon.com/
Founded in 2006, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005080/en/
Contact information
Brian Klotz, Nexon America
NA_pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom